Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
EV demonstrated antitumor activity in heavily pretreated HNC. Safety was consistent with the known safety profile of EV; no new safety signals were identified. These data support further evaluation of EV for advanced HNC not amenable to definitive local therapy.
Authors
- Changting Meng (ORCID: https://orcid.org/0000-0002-9438-5719)
- Michael Mihm
- Justine Y. Bruce (ORCID: https://orcid.org/0000-0002-5902-7430)
- Jason Kaplan (ORCID: https://orcid.org/0000-0003-3085-7147)
- Takao Fujisawa (ORCID: https://orcid.org/0009-0002-3438-5757)
- Paul Swiecicki (ORCID: https://orcid.org/0000-0003-2286-3555)
- Ari J. Rosenberg (ORCID: https://orcid.org/0000-0001-5908-0939)
- Emrullah Yilmaz (ORCID: https://orcid.org/0000-0003-2308-713X)
- Seema Rao Gorla (ORCID: https://orcid.org/0009-0006-5256-2189)
- J.L. Geiger (ORCID: https://orcid.org/0000-0003-4494-9843)
- Michele Wozniak
- Yupei Zhao (ORCID: https://orcid.org/0000-0001-7081-2299)
Institutions
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- University of Michigan (US)
- University of Chicago (US)
- University of Wisconsin Carbone Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1200/jco.24.00646
- Citations
- 20
- Primary Topic
- Ear and Head Tumors
- Type
- article
- Field-Weighted Citation Impact
- 5.65